Procoagulant phospholipid membrane (PS-membrane)

Phospholipid membranes on activated platelets serve as a critical catalytic surface for the blood coagulation cascade. In resting platelets, anionic phospholipids like phosphatidylserine (PS) are sequestered in the inner leaflet of the plasma membrane by the action of flippases (Zwaal & Schroit, 1997). Upon activation by agonists such as thrombin or collagen, platelets undergo a loss of membrane asymmetry mediated by scramblases, exposing PS on the outer surface (Lentz, 2003). This negatively charged environment facilitates the calcium-dependent binding and assembly of coagulation factor complexes, including the tenase (factors IXa/VIIIa) and prothrombinase (factors Xa/Va) complexes, which dramatically accelerates thrombin production (Heemskerk et al., 2013). Pathological exposure of these membranes is a hallmark of arterial and venous thrombosis, making them a target for site-specific antithrombotic therapies. Drugs targeting this surface, such as Annexin A5 derivatives or PS-binding antibodies, aim to shield the procoagulant surface and prevent excessive clot formation without the systemic bleeding risks associated with traditional anticoagulants (Schutters & Reutelingsperger, 2010).

Other names

Phosphatidylserine-exposed surfaceActivated platelet membraneAnionic phospholipid surfaceProcoagulant surfacePhospholipid membranes on activated platelets

Binding to and masking exposed anionic phospholipids, primarily phosphatidylserine, to prevent the assembly and activation of the tenase and prothrombinase complexes.